Global
TARGETED prOTEIN DEGRADERS
Unlock the most comprehensive insights into the rapidly evolving Targeted Protein Degradation (TPD) landscape with our latest market intelligence report. Covering 352 asset-based companies and 620+ active TPD assets, this report provides an in-depth analysis of PROTACs, DUB inhibitors, LYTACs, Molecular Glues, RNA degraders, and Degrader-Antibody Conjugates (DACs).
Explore cutting-edge technologies, key patents, and clinical advancements driving the next generation of targeted therapeutics. Whether you’re in drug discovery, business development, or competitive intelligence, this report is your essential guide to the future of protein degradation therapies.
providing intelligence at fingertips
23 Global Countries’ Covered
TPD Drug Developers Insights
Individual Drug Mechanism of Action & Drug Target
Covers complete Emerging Drug Targets Details with Emerging Technologies
INSIDE INTELLIGENCE - PREVIEW COPY
412 pages full of Insights
Degrader Modality | Active Targeted Protein Degraders Insights |
|---|---|
PROTAC / Heterobifunctional | 174 Drug Developers Developing PROTAC / Heterobifunctional
Degraders. (Complete Insights covering Technologies, Patents, Deals, Funding & Molecules in Development) |
Molecular Glue | 128 Drug Developers Developing Molecular Glue Degraders. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Degrader-Antibody Conjugates | 51 Drug Developers Developing Degrader-Antibody Conjugates
(DACs) Degraders. (Complete Insights covering Technologies, Patents, Deals, Funding & Molecules in Development) |
Deubiquitinases | 35 Drug Developers Developing Deubiquitinases (DUBs) &
Deubiquitinase-Targeting Chimeras (DUBTACs). (Complete Insights covering Technologies, Patents, Deals, Funding & Molecules in Development) |
LYTACs + | 22 Drug Developers Developing Lysosome-Targeting Chimeras
(LYTACs) & other Extracellular Degraders. (Complete Insights covering Technologies, Patents, Deals, Funding & Molecules in Development) |
AUTOTACs + | 10 Drug Developers Developing Autophagy-Targeting Chimeras (AUTOTACs) Degraders. (Complete Insights covering Technologies, Patents, Deals, Funding & Molecules in Development) |
How Intelligence offered by OmicsX is different from other resources
Better Than Others
Comparisons | Global Targeted Protein Degraders 2025 | Other Intelligence Sources |
|---|---|---|
Active Drug Developers | 352 Active Companies (Well Funded with clear defined clinical & early stage Pipeline) | 155-180 Companies (with many inactive and other domain companies) |
Drugs in Development | 622 TPD Drugs in Active Development(Complete Clinical & Preclinical Pipeline with indications, Drug Targets and Mechanism of Action) | 200 – 250 TPD Drugs (mainly focuses on Clinical Stage molecules) |
Bio-Partnering Details | 350+ TPD Exclusive Deals complete details.(Complete coverage on Deals, Funding & Partnering Activities, since company’s incorporation) | Limited to Database / Resource Subscribed to.(Also it may require mapping of events between two or more different resources and filtering TPD exclusive Deals). |
Single Step Connect | Over 750+ Key Decision Makers in 352 Companieswith valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available) | No Customized Solution Available in Market(Needs months of hard team work to prepare authentic business development tool. |
Trusted by
